NWBO
Northwest Biotherapeutics, Inc.0.2500
+0.0100+4.17%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
385.17MP/E (TTM)
-Basic EPS (TTM)
-0.06Dividend Yield
0%Recent Filings
8-K
8-K
Shareholders approve share increase
Northwest Biotherapeutics held its annual meeting on December 29, 2025, electing Pat Sarma to the board for three years and ratifying Cherry Bekaert as auditors. Stockholders approved increasing authorized common shares from 1.7B to 2.6B, filed effective December 30. Boosts flexibility for future financings. Say-on-pay passed at 77%.
8-K
Secures $5M convertible note
Northwest Biotherapeutics secured a $5 million convertible promissory note from Yorkville on November 14, 2025, funding Sawston, UK facility construction and operations. The 12-month note carries 5% OID, no interest, and converts at a discount to market price, capped at 1/5 monthly unless above $0.29. Funds target first Grade C manufacturing suite. No payments due until maturity.
10-Q
Q3 FY2025 results
Northwest Biotherapeutics narrowed its Q3 operating loss to $14.3M from $14.8M y/y, while nine-month operating loss eased to $46.4M from $48.0M y/y (derived), as R&D expenses dipped to $7.5M from $8.1M on lower manufacturing costs and stock comp. Revenues ticked up slightly to $200K from $357K y/y. Cash climbed to $4.6M from $2.2M year-end, fueled by $17.3M in equity raises and $12.7M new convertible notes, yet ops burned $30M y/y. Closed Advent BioServices acquisition Oct 24, 2025 for £1.4M cash plus net payables, gaining cryostorage assets with 19M company securities reverting—no goodwill noted. Debt stack hit $72.2M carrying value. Diluted EPS held at $(0.02), anti-dilutive. Cash burn persists.
8-K
Secures $5.5M loan
Northwest Biotherapeutics secured a $5,505,000 commercial loan from Streeterville Capital on October 27, 2025, maturing in 22 months with no repayments for the first 8 months and 14 amortized installments thereafter at 110% of principal plus 8% interest. It carries a 10% original issue discount and prepayment option with a 10% charge. Funds fuel ongoing operations. Default risks acceleration.
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
HCWB
HCW Biologics Inc.
1.78-0.09
IBRX
ImmunityBio, Inc.
2.16-0.06
NBTX
Nanobiotix S.A.
22.32+0.18
NVAX
Novavax, Inc.
6.54-0.04
NXTC
NextCure, Inc.
11.12-0.35
RENB
Lunai Bioworks Inc.
1.42+0.00
WHWK
Whitehawk Therapeutics, Inc.
2.40+0.04